Financing weighs now, pipeline pays later
23/06/26 -"Our estimates for 2026 and 2027 are significantly affected by net financial expenses. The firm raised $5.5bn to fund the Merus acquisition, which is expected to be accretive to EBITDA, with projected ..."
Pages
48
Language
English
Published on
23/06/26
You may also be interested by these reports :
23/06/26
Our estimates for 2026 and 2027 are significantly affected by net financial expenses. The firm raised $5.5bn to fund the Merus acquisition, which is ...
19/06/26
Evaluating Pharma’s Defences
17/06/26
Our target price is reduced to CHF94 (from CHF97) on the back of a lower sales base. We have also adjusted forward years’ growth, slightly increasing ...
15/06/26
The target price is upgraded on the back of higher margins in 2026. The EBITDA margin is lifted from 15.4% to 17.9% for the full year (guidance is ...